Actavis reaches agreement with Cephalon over patent

DUBLIN — Actavis last week announced that it has reached an agreement with Cephalon to settle all outstanding patent litigation associated with Actavis' generic version of Nuvigil (armodafinil tablets).



As part of the agreement, Cephalon will allow Actavis to market generic versions of 100-mg and 200-mg Nuvigil beginning June 1, 2016 or earlier under certain conditions. Cephalon also will grant Actavis a license to market generic versions of 50-mg, 150-mg and 250-mg Nuvigil beginning 180 days after the initial launch of the generic versions of those strenghts. Additional details were not disclosed.



Nuvigil is used to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, shift work disorder or narcolepsy, the company stated. Nuvigil had sales in the United States of approximately $437 million for th 12 months ending Feb. 28, according to IMS Health data.